Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KATP in the Progression of Type 2 Diabetes
NCT06830096Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of glipizide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Insulin secretion at 90 minutes. Started Mar 2025; status: recruiting.
02
Drugs
glipizide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06830096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830096.